Arvinas to Participate in Upcoming Investor Conferences
04 mars 2025 16h05 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Breast Cancer Drugs Market Size is Projected to Reach USD 80.34 Billion by 2033, Growing at a CAGR of 8.90%: Straits Research
04 mars 2025 09h50 HE
|
Straits Research Private Limited - Garner Insights
New York, United States, March 04, 2025 (GLOBE NEWSWIRE) -- Breast cancer is the prevailing ailment in the population, predominantly affecting women who are witnessing an increase in disease...
Irazú Oncology Secures Bridge Funding, Expands Leadership Team and Facilities
04 mars 2025 08h30 HE
|
Irazu Oncology
Dr. Mayukh Das, joined Irazú as CMO, bringing extensive oncology drug development experience from leadership roles at global pharmaceutical companies.
Woodlands Cancer Institute Relocates Its Medical Oncology Clinic in The Woodlands, Texas
04 mars 2025 08h00 HE
|
American Oncology Network
Woodlands Cancer Institute Relocates Its Medical Oncology Clinic in The Woodlands, Texas to continue providing enhanced cancer care to the local community.
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
27 févr. 2025 16h05 HE
|
Cardiff Oncology, Inc.
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40...
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
27 févr. 2025 08h00 HE
|
Compass Therapeutics
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the...
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
26 févr. 2025 16h02 HE
|
Revolution Medicines, Inc.
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data...
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
26 févr. 2025 10h45 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
26 févr. 2025 08h00 HE
|
PDS Biotechnology Corporation
PDS Biotech announced clinical results in the Journal of the American Medical Association (JAMA) Oncology.
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
26 févr. 2025 07h00 HE
|
Wugen
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer